Showing 1 posts of 1 posts found.
Oxeltis, a French contract research organisation specialising in medicinal and organic chemistry, has announced that it will lead the BUNYANTIVIR …
Survey highlights mental health burden among rare disease patients and families
Addressing the rheumatic disease diagnostic gap in primary care
How chronic disease creates opportunity on diagnostic and therapeutic pipelines
EnteroBiotix appoints former GSK Chief Medical Officer to board
Stryker invests US$400m in CMR Surgical and secures option to acquire business